QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World’s Poorest Countries

GERMANTOWN, Maryland and HILDEN, Germany, May 3, 2012 /PRNewswire/ –

        - Point-of-Care Diagnostics Initiative is part of Grand Challenges in Global
          Health program funded by Bill & Melinda Gates Foundation and Grand Challenges Canada
        - QIAGEN's expertise and technologies will aid effort to create a low-cost
          portable testing platform for molecular diagnostics in the developing world
        - Development expected to be completed by 2014, enabling rapid integration of
          tests and transfer into clinical practice to save lives and reduce burden from
          infectious diseases

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has
joined the Point-of-Care Diagnostics (POC Dx) Initiative led by the Bill & Melinda Gates
Foundation and Grand Challenges Canada to create a new molecular diagnostics platform to
serve resource-poor regions of the world.

QIAGEN has already started the development of a portable instrument based on its
advanced molecular testing technologies for Point of Need applications. The development of
affordable and portable diagnostic systems is one of the 16 “Grand Challenges in Global
Health,” an initiative that seeks to enhance healthcare in the world’s poorest countries.

QIAGEN is joining more than 20 nonprofit, academic and corporate organizations in the
POC Dx Initiative, which aims to catalyze a “diagnostics revolution” for the developing
world. The goal of this initiative is to create new platforms that enable high-quality,
low-cost point-of-care diagnosis and thereby make systematic and sustainable improvements
in healthcare in the developing world.

QIAGEN’s role is to develop an easy-to-use, portable molecular testing device that can
perform diagnostic tests in the field, far from hospital or laboratory infrastructure.
This task also encompasses the creation of a corresponding assay technology suited for use
in low-resource settings. This project is part of the technology development phase of the
POC Dx initiative, which will then integrate successful technologies into a
multifunctional point-of-care platform. The POC Dx Initiative targets a broad array of
related projects, such as putting together standards for diagnostics best suited to remote
and impoverished settings, creating components such as low-cost devices to collect blood
samples, or planning for the future integration of diagnostics into delivery of care in
these areas.

“We are pleased to further expand our collaboration with the Bill & Melinda Gates
Foundation to help bring the power of advanced molecular diagnostics to battle infectious
and other diseases in developing regions. The new low-cost portable testing devices
currently under development are intended to enable reliable, quick diagnosis and timelier
treatment of patients. We believe that modern diagnostic technologies can have a very
significant positive impact on developing countries, helping to save lives, reduce
economic impacts, and curtail the spread of infectious diseases,” said Dr. Ellen Sheets,
Chief Medical Officer of QIAGEN. “QIAGEN has already placed thousands of Point of Need
testing devices which are being used in a variety of applications in Molecular Diagnostics
and Applied Testing. This experience will be instrumental in developing a new platform
designed especially for the healthcare needs of developing countries and low-resource
regions.”

“The Point-of-Care Diagnostics Initiative seeks to transform the way we diagnose and
treat patients in the world’s poorest countries,” said Gene Walther, Deputy Director
Diagnostics at the Bill & Melinda Gates Foundation. “We hope that these groundbreaking
ideas lead to new tools that can quickly diagnose disease and accelerate access to
lifesaving health interventions for those in greatest need.”

Through its own QIAGEN cares program, QIAGEN is working on multiple fronts to improve
access to screening for infectious diseases in emerging countries. QIAGEN has previously
collaborated with the Bill & Melinda Gates Foundation and PATH, an international nonprofit
organization, in developing the careHPV Test, a state-of-the-art diagnostic specifically
designed for low-resource settings to screen women for human papillomavirus (HPV), the
primary cause of cervical cancer. The careHPV Test can be performed without access to a
laboratory infrastructure and offers results in a few hours, a critical feature for women
who travel to clinics from isolated villages and need to be treated the same day.

QIAGEN collaborates with a number of public health and nonprofit agencies to make its
HPV screening technologies available in resource-poor areas of Africa, Asia and Latin
America. In Applied Testing, the company is collaborating with the UN Food and Agriculture
Organization (FAO) and the International Atomic Energy Agency (IAEA) in a pilot project
designed to contain devastating animal diseases in developing countries using portable
testing devices provided by QIAGEN.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample &
Assay Technologies that are used to transform biological materials into valuable molecular
information. Sample technologies are used to isolate and process DNA, RNA and proteins
from biological samples such as blood or tissue. Assay technologies are then used to make
these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than
500 products around the world, selling both consumable kits and automation systems to
customers through four customer classes: Molecular Diagnostics (human healthcare), Applied
Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and
biotechnology companies) and Academia (life sciences research). As of March 31, 2012,
QIAGEN employed approximately 3,900 people in over 35 locations worldwide. Further
information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended.
To the extent that any of the statements contained herein relating to QIAGEN’s products,
markets, strategy or operating results, including without limitation its expected
operating results, are forward-looking, such statements are based on current expectations
and assumptions that involve a number of uncertainties and risks. Such uncertainties and
risks include, but are not limited to, risks associated with management of growth and
international operations (including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating results and allocations
between customer classes, the commercial development of markets for our products in
applied testing, personalized healthcare, clinical research, proteomics, women’s
health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships
with customers, suppliers and strategic partners; competition; rapid or unexpected changes
in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due
to general economic conditions, the level and timing of customers’ funding, budgets and
other factors); our ability to obtain regulatory approval of our products; difficulties in
successfully adapting QIAGEN’s products to integrated solutions and producing such
products; the ability of QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors’ products; market acceptance of QIAGEN’s new
products, the consummation of acquisitions, and the integration of acquired technologies
and businesses. For further information, please refer to the discussions in reports that
QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

        Contacts:

        Public Relations:
        Dr. Thomas Theuringer
        Director Public Relations
        +49-2103-29-11826
        +1-240-686-7425

        Email: pr@qiagen.com

http://www.twitter.com/qiagen

http://www.qiagen.com/about/press

        Investor Relations:
        John Gilardi
        VP Corporate Communications
        +49-2103-29-11711
        +1-301-240-686-2222

        Albert F. Fleury
        Investor Relations North America
        +1-301-944-7028

        Email: ir@qiagen.com

http://www.qiagen.com/about/investorrelation

SOURCE QIAGEN N.V.